Notice NOT-CA-22-012 from the NIH Guide for Grants and Contracts

Notice NOT-ES-22-001 from the NIH Guide for Grants and Contracts

Notice NOT-RM-22-003 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-020 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-022 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-021 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-011 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-010 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-028 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide investigators with a mechanism to access contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.

Funding Opportunity PAR-22-030 from the NIH Guide for Grants and Contracts. The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.

Funding Opportunity PAR-21-353 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

Funding Opportunity PAR-21-354 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

Funding Opportunity PAR-21-355 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

Notice NOT-NR-22-001 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-020 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-035 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-030 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-21-061 from the NIH Guide for Grants and Contracts. The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-CA-21-NNN).

Notice NOT-CA-22-007 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-009 from the NIH Guide for Grants and Contracts